Dynamics of milk leukocytes in response to intramammary infusion of amoxicillin plus sulbactam during bovine subclinical mastitis

Abstract

ABSTRACT:The therapeutic potential of amoxicillin plus sulbactam and its effect on dynamics of milk leukocytes in bovine sub clinical mastitis were investigated in this study. Therapeutic efficacy was measured by somatic cell count and total bacterial count of the milk, whereas, the dynamics of milk leukocytes were assessed by measuring phagocytosis, hydrogen peroxide production, myeloperoxidase and lactoperoxidase enzyme levels in the milk leukocytes. Forty-five crossbred cows were randomly divided into three equal groups. Group I consisting of 15 cows served as healthy control, whereas 30 cows (sub clinical mastitis) were randomly divided into Groups II and III on the basis of positive reactions in the California Mastitis Test. Group II cows received 300mg of amoxicillin plus sulbactam twice daily for three days and Group III received sterile 5 ml phosphate buffer saline (pH 7.4) for three days. Both treatments were administered via the intramammary route. Observations were made up to 15 days after initiation of treatment. The results revealed a pronounced drop in somatic cell count and total bacterial count, whereas significant (P < 0.05) enhancement of phagocytic activity (42.20%), hydrogen peroxide production (29.46%), myeloperoxidase (49.27%) and lactoperoxidase (147.10%) enzyme levels in the milk leukocytes in Group II cows during post treatment periods were observed. Such changes were statistically non-significant in Group III cows. The results of the present study indicate that intramammary use of amoxicillin plus sulbactam augments the bactericidal function of milk leukocytes during bovine sub clinical mastitis and demonstrate the strong therapeutic potential against bovine subclinical mastitis.

Clinical field trial of parenteral amoxicillin for the treatment of clinical and subclinical mastitis in smallholder dairy farms in the upper region of Northern Thailand

“…Because amoxicillin has the same pharmacokinetic features as those of parenteral penicillin G, a better efficacy for treating mastitis through the intramuscular route is anticipated [14]. Moreover, amoxicillin, alone or in combination with β-lactamase inhibitors, has been widely used to treat clinical mastitis in dairy cows [15,16]. According to Roberson et al [15], IMM amoxicillin appeared to be an effective treatment for environmental streptococci in cases of mild or moderate clinical mastitis.…”

“…According to Roberson et al [15], IMM amoxicillin appeared to be an effective treatment for environmental streptococci in cases of mild or moderate clinical mastitis. De and Mukherjee [16] reported a substantial reduction in SCC and total bacterial count in cows that were provided IMM administrations of 300 mg of amoxicillin + sulbactam during the posttreatment period. Similarly, another study reported a successful clinical recovery of bovine mastitis in lactating cows treated with a combination of amoxicillin and clavulanic acid by IMM infusion [17].…”

“…Although numerous studies have been conducted to evaluate the efficacy of IMM amoxicillin in bovine mastitis [15][16][17], there are scarce investigations on the efficacy of parenteral amoxicillin in treating subclinical and clinical mastitis during lactation. Therefore, this study aimed to evaluate the treatment efficacy of parenteral amoxicillin in clinical and subclinical mastitis in smallholder dairy farms in the upper region of Northern Thailand.…”

Pharmacokinetics and pharmacodynamics of a novel amoxicillin/sulbactam/prednisolone intramammary infusion in lactating cows after repeated administrations

“…It has been observed that AMX alone or in combination with β-lactamase inhibitors is potentially useful for the treatment of mastitis caused by pathogenic organisms (Roberson et al 2004;Sharma et al 2010). A very effective clinical recovery of bovine mastitis was reported in lactating cows treated with intramammary infusion of AMX plus SUL (DeOliveira et al 2000;Sharma et al 2010;De and Mukherjee 2012). Synulox ® LC, a combination drug comprising AMX (200 mg), clavulanic acid (CLAV, 50 mg), and PSL (10 mg) in a 3 g syringe, was developed by Pfizer Pharmaceuticals Inc. (New York, NY, USA.)…”

Retraction：Pharmacokinetics and Pharmacodynamics of a Novel Amoxicillin/Sulbactam/Prednisolone Intramammary Infusion in Lactating Cows after Repeated Administrations

“…It has been observed that AMX alone or in combination with β-lactamase inhibitors is potentially useful for the treatment of mastitis caused by pathogenic organisms [19,21]. A very effective clinical recovery of bovine mastitis was reported by lactating cows treated with intramammary infusion of AMX plus SUL [10][11]21]. Synulox ® LC, a combination drug that comprising AMX (200 mg), clavulanic acid (CLAV, 50 mg) and PSL (10 mg) in a 3 g syringe, was developed by Pfizer Pharmaceutical Inc. (New York, NY, U.S.A.) and used for the treatment of bovine mastitis.…”